Clinical trials
Metastatic clinical trials
Below are recruiting metastatic clinical trials, each written for real people, not researchers. We’re tracking 2,367 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06413992RecruitingPhase 2
Camrelizumab plus fluzoparib for TP53-mutated endometrial cancer
This trial tests a combination of two drugs, camrelizumab (an immunotherapy) and fluzoparib (a PARP inhibitor), for people with a specific type of endometrial cancer that has a TP53 gene mutation. It may offer a new option for advanced or recurrent disease after limited prior treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06416007RecruitingPhase 2
Lattice radiation for large tumor palliation
This study tests a new way to deliver radiation called lattice therapy for people with large solid tumors that are causing symptoms. It aims to give a stronger radiation dose to help shrink the tumor and relieve discomfort.
Cincinnati, OhioAges 18 years+ - NCT06421298RecruitingPhase 2
Tafolecimab and sintilimab plus chemo for advanced lung cancer
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06422455Recruiting
Genetic testing for underserved cancer patients
This study offers free genetic testing to cancer patients and their healthcare providers. It aims to help people who may not have easy access to genetic testing understand their cancer risk.
Los Angeles, CaliforniaAges 18 years+ - NCT06429813Recruiting
Remote exercise program for men with metastatic prostate cancer
This trial tests whether a remotely supervised exercise program (walking and stationary cycling) can help men with metastatic prostate cancer who are starting hormone therapy. Participation involves following an exercise plan at home and may help manage side effects.
Charlottesville, VirginiaAges 18 years+ - NCT06439771RecruitingPhase 2
Testing YL202 for advanced breast cancer
This trial tests a new drug called YL202 for people with advanced breast cancer. It is for those who have already tried certain targeted treatments (HER2 or TROP2 antibody-drug conjugates) and they stopped working. The goal is to see if YL202 can help shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06441773Recruiting
Lung rehab for advanced lung cancer on maintenance therapy
This study tests if a respiratory (breathing) rehabilitation program can improve quality of life for people with advanced non-small cell lung cancer who are on maintenance treatment after initial chemotherapy and immunotherapy.
BrestAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
Study of new RAS inhibitors for GI solid tumors
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
Chandler, ArizonaAges 18 years+ - NCT06446401Recruiting
Triple vs double therapy for widespread prostate cancer
This trial compares two treatment approaches for men whose prostate cancer has spread widely and is still responding to hormone therapy. It tests whether using three drugs together (triple therapy) works better than two drugs (double therapy) to control the cancer longer.
Uppsala, Region UppsalaAges 18 years+ - NCT06449989Recruiting
Comparing genetics of colorectal cancer and its brain spread
This study compares the genetics of the original colorectal cancer with the cancer that has spread to the brain. It aims to understand how the tumor changes when it metastasizes, which may help guide future treatments.
Moscow, MoscowAges 18 years+ - NCT06450548Recruiting
PSMA and FDG PET scans before 177Lu-PSMA therapy
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
RouenAges 18 years+ - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06456515Recruiting
Regorafenib, sintilimab, and electroacupuncture for advanced colorectal cancer
This trial tests a combination of two drugs (regorafenib and sintilimab) plus electroacupuncture for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to see if this triple therapy can help shrink tumors or slow the cancer's growth.
ChangzhouAges 18–75 - NCT06457503RecruitingPhase 4
Toripalimab plus chemo for advanced nasopharyngeal cancer
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people whose nasopharyngeal cancer has come back or spread. It is for those who haven't yet received other treatments for this advanced stage.
Little Rock, ArkansasAges 12 years+ - NCT06459687RecruitingPhase 3
Socazolimab for first-line treatment of advanced cervical cancer
This phase 3 trial tests a new immunotherapy drug called socazolimab combined with chemotherapy as a first treatment for cervical cancer that has come back, spread, or cannot be removed with surgery or radiation. The goal is to see if it helps shrink tumors and improves survival.
Hefei, AnhuiAges 18–75 - NCT06459791Recruiting
Personalized treatment for advanced breast cancer using lab-grown tumor models
This trial tests a personalized approach to cancer treatment. Doctors will grow a ‘mini-tumor’ from a biopsy of your cancer in the lab to help find the best therapy for you. It is for people with advanced breast cancer that has not responded well to standard treatments.
ParisAges 18 years+ - NCT06468280RecruitingPhase 2
Immunotherapy and chemo with surgery for limited-spread stomach cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) plus chemotherapy or targeted therapy, followed by surgery, for people with stomach cancer that has spread to a limited number of other sites. The goal is to see if this approach can help shrink the cancer enough to make surgery more effective.
Shanghai, Shanghai CityAges 18–79 - NCT06469008RecruitingPhase 1
Study of BL-B16D1 for advanced head and neck cancer and other solid tumors
This study tests a new drug, BL-B16D1, for people with advanced head and neck cancer or other solid tumors that have not been helped by standard treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06471673RecruitingPhase 1/Phase 2
BRIA-OTS cellular immunotherapy for metastatic breast cancer
This study tests an investigational cellular immunotherapy called BRIA-OTS for people with metastatic breast cancer that has spread and is no longer responding to standard treatments. It aims to help the immune system fight cancer cells.
Santa Monica, CaliforniaAges 18 years+ - NCT06474676RecruitingPhase 1
Modified immune cell therapy for advanced sarcoma
This trial tests a new treatment using your own immune cells (TILs) that have been modified to attack sarcoma tumors. It is for people with advanced soft tissue or bone sarcoma who have already tried at least one other therapy.
Houston, TexasAges 12 years+ - NCT06478693RecruitingPhase 1
Study of MT-303 for advanced liver cancer
This study tests a new drug called MT-303 for people with advanced liver cancer (HCC) or other cancers that produce a protein called GPC3. The drug is designed to target and attack the cancer cells. The trial is in an early phase, so it is looking at safety and how well the drug works.
Sydney, New South WalesAges 18 years+ - NCT06479239RecruitingPhase 1/Phase 2
Immune cell therapy for advanced pancreatic cancer
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
Charlottesville, VirginiaAges 18 years+ - NCT06479811RecruitingPhase 1
Radioactive drug for advanced neuroendocrine and other cancers
This trial tests a new radioactive drug, [212Pb]VMT-Alpha-NET, that targets a protein on certain cancer cells. It is for people with specific types of advanced cancers that have gotten worse and are not responding to standard treatments.
Bethesda, MarylandAges 18–120
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic?
- Yes. Clin2 currently lists 2,367 recruiting metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.